BioMarkSN

Offentlig prosjektsammendrag

CardiNor AS is a Norwegian biotech company established in June 2015 to develop and commercialise assays for secretoneurin (SN), an important new biomarker for cardiovascular disease (CVD). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte Ca2+ handling (1). This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. We are currently developing an easy to use ELISA (enzyme-linked immunosorbent assay) blood test to address the vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring. This will also involve clinical documentation, regulatory filing and market awareness programs. Cardiomyocyte Ca2+ imbalance is at the core of most triggered arrhythmias in CVD, but current biomarkers (troponins and BNP) do not reflect Ca2+ regulation. Accordingly, methods to identify and monitor patients with cardiomyocyte Ca2+ imbalance and increased risk of VT/VF are highly warranted. As the only biomarker associated with Ca2+ status, SN is ideally suited for this purpose. Moreover, high SN concentrations are also a strong indication of the need to follow up with ECGs, echocardiography, and other examinations (angiography, cardiac MRI, PET-CT, etc.) to determine whether there are signs of structural or functional heart disease. CardiNor is now developing an easy-to-use blood test for SN to help identify patients with heart disease who will benefit from ICD treatment. The current technology available for measuring SN is an RIA (radioimmunoassay) not suitable for routine or clinical use. We are developing a new test based on ELISA technology that is very well established in both clinical research and routine and can easily be adopted on platforms such as Cobas by Roche and Architect by Abbott.